-

New Study finds Volumetric Absorptive Micro-Samplers (VAMS) Prove to be Useful Self-Collection Tools for Assessing Human Exposure to PFAS

LUXEMBOURG--(BUSINESS WIRE)--The American Chemical Society’s Environmental Science and Technology journal recently published a study, “A Self-Collection Blood Test for PFASs: Comparing Volumetric Micro-Samplers with a Traditional Serum Approach” which reports a test developed by Eurofins Environment Testing is a viable self-collection tool for assessing human exposure to PFAS. This method effectively quantifies PFAS in whole blood samples collected by volumetric micro samplers (VAMS).

PFAS, short for per- and polyfluoroalkyl substances, are a class of very stable compounds with unique characteristics making them largely unsusceptible to degradation. Some PFAS accumulate and persist in the environment and in humans. Accumulation of some PFAS in blood has been linked to several negative health outcomes, leading to a need for more epidemiological research.

Historically, serum has been used to conduct biomonitoring of PFAS. Traditional blood collection (serum or plasma) for biomonitoring can be costly and challenging to coordinate and requires the support of a trained phlebotomist. Recent studies have indicated whole blood, collected easily with VAMS, to be a better approach for assessing exposure to a broader suite of PFAS.

Results from the American Chemical Society’s Environmental Science and Technology journal’s study included the sampling and testing of individuals through traditional serum and self-collected VAMS. PFAS levels in serum were highly correlated with measurements in capillary VAMS, indicating that VAMS are useful self-collection tools for assessing human exposure to PFAS.

"This research study is a critical effort, as it provides us with confidence that self-collected blood samples provide just as good – if not, in some cases, better – data on human exposure,” said Christopher P. Higgins, a co-author of the study and University Distinguished Professor of Civil and Environmental Engineering at Colorado School of Mines. “Just as importantly, though, these are much easier to collect than traditional serum samples, and thus this really opens the door for bigger-scale PFAS exposure assessment efforts.”

Self-collected blood samples can help support large scale biomonitoring programs and epidemiologic studies providing a promising solution to several obstacles encountered in biomonitoring studies.

This study was co-authored by Andrew Patterson, Thep Phomsopha, and Eric Redman, all scientists from within the Eurofins Environment Testing network of companies in the USA. Additional co-authors include Courtney Carignan and Rachel Bauer with Michigan State University and Heather Stapleton with Duke University.

Read the published paper in Environmental Science and Technology here.

About Eurofins Environment Testing – USA

The Eurofins environmental laboratories network in the US performs analysis of drinking water, groundwater, seawater, soil, air, and tissue using state-of-the-art analytical methods to assess quality and impact on health and the environment.

Contacts

Further information:
Brooke Maharg
Brooke.Maharg@ET.EurofinsUS.com

Eurofins Environment Testing – USA

BOURSE:ERF

Release Versions

Contacts

Further information:
Brooke Maharg
Brooke.Maharg@ET.EurofinsUS.com

More News From Eurofins Environment Testing – USA

Eurofins Scientific SE: Disclosure of Total Number of Voting Rights and Number of Shares in the Capital at 30 November 2025

LUXEMBOURG--(BUSINESS WIRE)--Regulatory News: Eurofins Scientific SE (Paris:ERF): ANNEXE B Form to be used for the disclosure of the total number of voting rights and capital, in accordance with the law and grand-ducal regulation of 11 January 2008 on transparency requirements for issuers of securities Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedi (including the issuer ID allocated by the CSSF EUROFINS SCIENTIFIC SE – E1013 Identity of t...

Eurofins Medical Device Services Launches first GMP PFAS Screening and Testing Solutions for Medical Devices

LANCASTER, Pa.--(BUSINESS WIRE)--Eurofins Medical Device Services North America, part of a global network of over 20 medical device testing laboratories and a leading medical device solutions partner, recently launched a GMP PFAS testing and screening solution, the first developed and commercialized for the medical device industry. This offering provides insights to medical device manufacturers as they navigate the complex and evolving global regulations surrounding PFAS, ultimately contributin...

Eurofins: Weekly Report on Share Repurchases From 24th November to 28th November 2025

LUXEMBOURG--(BUSINESS WIRE)--Regulatory News: Eurofins (Paris:ERF): Name of the Issuer Identify code of the Issuer Transaction day Identify code of the financial instrument Total daily volume (in number of shares) Daily weighted average purchase price of the shares Market (MIC Code) EUROFINS SCIENTIFIC 529900JEHFM47DYY3S57 24/11/2025 FR0014000MR3 20 000 58.4487 XPAR EUROFINS SCIENTIFIC 529900JEHFM47DYY3S57 25/11/2025 FR0014000MR3 20 000 58.6804 XPAR EUROFINS SCIENTIFIC 529900JEHFM47DYY3S57 26/1...
Back to Newsroom